• Home
  • About Us
    • About Us
    • Leadership Team
  • Science
    • Biologics
    • Biomanufacturing
    • Pipeline
  • Investors
    • Overview
    • SEC Filings
    • Press Releases
    • Presentations
    • Corporate Governance
    • Investor Resources
      semaglutide
      • Email Alerts
      • FAQs
      • Tax Documents
  • Careers
  • Contact Us

New Valion Bio Board Chair Thomas Jensen Brings Biotech Turnaround Experience to the Advancement of Entolimod

Oct 5, 2026 | Press Releases

Jensen, who as CEO led Nasdaq-listed biotech Allarity Therapeutics’ refocusing around a single lead asset, cites Valion’s rare combination of government funding, FDA designations, human safety data and wholly owned U.S. manufacturing SAN ANTONIO, TX /...

Valion Bio and Shear Kershman Laboratories Successfully Formulate Oral Mucosal Entolimod; Valion Sees Potential for Multi-Fold Expansion of Long-Term Opportunity

Sep 30, 2026 | Press Releases

Needle-free program creates a potential second development pathway alongside Valion’s injectable Entolimod programNext study will test whether the formulation delivers measurable amounts of Entolimod into the bloodstream SAN ANTONIO, TX / ACCESS Newswire /...

Valion Appoints Life Sciences Veteran Dean Zikria as Interim CEO and Announces Board Leadership Transitions

Sep 23, 2026 | Press Releases

Leadership changes strengthen alignment and execution as Company advances Entolimod and evaluates strategic, commercial and government opportunities SAN ANTONIO, TX / ACCESS Newswire / September 23, 2026 / Valion Bio, Inc. (NASDAQ:VBIO) (“Valion” or the...

Valion Bio Regains Compliance with NASDAQ Minimum Bid Price Listing Rule

Sep 22, 2026 | Press Releases

Nasdaq confirms compliance with continued listing standard and closes the matter SAN ANTONIO, TX / ACCESS Newswire / September 22, 2026 / Valion Bio, Inc. (Nasdaq:VBIO) (“Valion” or the “Company) announced today that it has received formal written...

Valion Bio Announces Changes to Management and Board of Directors

Sep 1, 2026 | Press Releases

Current CFO, Lisa Wolf named President and COO, assuming expanded executive and operational leadership. Jared Malbin and Thomas Jensen appointed as directors.Lead Asset Positioned for Significant Markets: Entolimod targets the projected $7.8 billion Acute Radiation...
« Older Entries
Next Entries »

Recent Posts

  • Valion Bio Welcomes Former U.S. Army Regulatory Leader and Biotech CEO Dr. Armand Balboni as Advisor in Run-up to Entolimod Therapeutic Efficacy Data Readout
  • Valion Bio Reports Completion of 200-Liter Entolimod Production Run; Material Supplying Ongoing AFRRI Study
  • Valion Bio Reinforces Commitment to American Troops; Discusses Entolimod with Attendees at RW Baird’s National Security Conference
  • Valion Bio Advancing Entolimod into U.S. Government-Funded Therapeutic Efficacy Study Following Positive Safety Results
  • Valion Bio Announces Positive Safety Results From U.S. Government-Funded Entolimod Study, Paving Way For Therapeutic Efficacy Evaluation

Recent Comments

No comments to show.
©2026 Valion Bio

Privacy Policy

For ClearUP customer questions regarding warranty or other device inquiries, please reach out to customerservice@tivichealth.com.